IL2 and neoplasm: Injection of fluorescently labelled effector cells (1 x 10(6)) including naive splenocytes, T-cell enriched populations and ex vivo interleukin 2 (IL-2)-activated splenocytes all migrated to and flowed through both the tumour and the normal microcirculation, with negligible adhesion.